Arterys Oncology DL

by Arterys  · Based in United States → — AI-powered, cloud-based medical imaging for enhanced diagnostic accuracy and workflow efficiency.
Oncology Radiology

Custom plan
Regulatory Status Disclosed

Overview

Arterys Oncology DL is an FDA-cleared, AI-powered medical imaging software designed to enhance diagnostic efficiency and accuracy for oncologists. It leverages deep learning to automate the segmentation and tracking of lung nodules and liver lesions in CT and MRI scans, providing accurate and editable results comparable to manual segmentations by experienced clinicians.

Operating on the Arterys Medical Imaging Cloud (MICA) platform, the solution integrates seamlessly into existing PACS or EHR workflows, making it accessible from validated devices via the cloud. Arterys aims to improve physician experience, diagnostic accuracy, treatment planning, and patient outcomes by reducing tedious manual tasks and providing quantitative, intelligent insights.

The platform supports 2D and 3D visualization, semi-automatic volumetric segmentation, co-registration, longitudinal tracking, and data reporting based on Lung-RADS and LI-RADS guidelines. Arterys’ cloud-native architecture reduces IT overhead and allows healthcare facilities of any size, from major hospitals to small clinics, to access cutting-edge AI capabilities.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis
  • Cloud-based platform
  • Automated segmentation of lung nodules and liver lesions
  • Longitudinal tracking of lesions
  • 2D and 3D visualization
  • Co-registration
  • Automated reporting (Lung-RADS, LI-RADS, RECIST)
  • Integration with PACS and EHR
  • Real-time collaboration
  • Customizable workflows

Use Cases

  • Automated detection and quantification of lung nodules in CT scans
  • Automated detection and quantification of liver lesions in CT and MRI scans
  • Longitudinal tracking of tumors and lesions over time
  • Assessing response to cancer treatment
  • Standardized reporting for oncology workflows
  • Enhancing diagnostic accuracy and efficiency for oncologists and radiologists

What Physicians Need to Know

Evidence Base
Arterys Oncology DL leverages deep learning algorithms and supports data reporting based on Lung-RADS and LI-RADS guidelines. Its workflows and calculations are based on published industry technical standards and peer-reviewed publications.
Clinical Validation Studies
The software is FDA-cleared. Non-clinical verification and validation testing established that the device meets its design requirements and intended use, demonstrating safety and effectiveness comparable to predicate devices. It has been validated to produce results with accuracy equal to segmentations performed manually by experienced clinicians.
Alert Fatigue Management
Not explicitly mentioned in provided information; the tool primarily focuses on image analysis and quantification rather than generating alerts in a traditional CDS sense.
Override Rate Data
Not explicitly mentioned in provided information. Clinicians retain the ultimate responsibility for diagnosis and have the capability to edit automated segmentations.
Guideline Update Frequency
Not explicitly mentioned in provided information. The software supports reporting based on Lung-RADS and LI-RADS guidelines.
Clinical Workflow Integration
Arterys Oncology DL is designed to support the oncological workflow by automating tedious, time-consuming manual steps like segmentation. It integrates with PACS and runs on the Arterys Medical Imaging Cloud (MICA) platform, accessible via a compatible web browser. It also enables real-time collaboration.
Decision Audit Trail
The Arterys MICA platform, which hosts Oncology DL, includes audit logs for security.
Physician Tip

Arterys Oncology DL is an AI-powered tool designed to enhance efficiency and consistency in the evaluation of lung and liver lesions from CT and MRI scans by automating segmentation and tracking. While it provides accurate, editable results comparable to manual segmentations, the clinician retains ultimate responsibility for the final diagnosis and treatment decisions. Leverage its capabilities for quantitative data, longitudinal tracking, and standardized reporting (Lung-RADS, LI-RADS) to streamline your workflow and improve diagnostic confidence.

The Arterys Oncology DL solution is cloud-based and integrates directly into existing PACS or EHR-driven workflows, making it a natural extension of current practices. It operates on the Arterys MICA platform, ensuring HIPAA compliance and patient data privacy across multiple countries. Integration partners include CrelioHealth LIMS, ARIA Oncology Information System, MOSAIQ Radiation Oncology, CARESTREAM Vue RIS, PacsCube, virtualPACS Gateway, Ambra Health, and MiNNOVAA PACS.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Custom plan
DeploymentCloud-based (SaaS)
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Radiology

What the Web Says

Arterys Oncology DL is a cloud-based AI imaging software designed to assist radiologists and oncologists in measuring and tracking tumors and potential cancers. It leverages deep learning to automate the segmentation of lung nodules and liver lesions, aiming to improve diagnostic accuracy and efficiency. The software integrates with existing hospital systems and is accessible via a web browser, complying with patient data privacy and security requirements in numerous countries.

Overall: Positive

Strengths

  • Automated segmentation and tracking of lung nodules and liver lesions, with accuracy comparable to manual methods.
  • Cloud-based platform (MICA) is easier to deploy than on-premise systems and offers seamless collaboration for second opinions.
  • Reduces variability and subjectivity in clinical diagnoses and alleviates radiologist workloads.
  • Provides intuitive LI-RADS workflow and score calculation.
  • Vendor-agnostic and integrates with PACS, RIS, EMR, and dictation software.
  • FDA cleared for clinical use, with multiple FDA approvals for its AI algorithms across various specialties.

Limitations

  • Limited public reviews available on platforms like G2 and Capterra, making it difficult to gauge widespread user satisfaction.
  • While the technology is advanced, the core information found is from press releases and company statements, which may not reflect independent user experiences.
  • No specific negative feedback from physicians or healthcare IT professionals was readily available in the search results.
  • The initial deep learning workflows were focused on liver MRI/CT and lung CT scans, with plans for expansion to other solid tumors, implying a phased rollout of capabilities.
  • The software is a support tool and does not directly generate diagnoses, requiring interpretation by trained professionals.

Based on reviews from: PR Newswire, Forbes, G2, Applied Radiology, SoftwareWorld, Tempus, Fierce Biotech, DAIC

Last updated: 2026-07-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Arterys Oncology DL

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Imaging Technology News
Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning
Arterys announced its fifth 510(k) clearance from the FDA for the Arterys Oncology AI Suite, an AI-based, cloud-based medical imaging software. This new software helps clinicians measure and track tumors or potential cancers, and easily apply radiological standards for liver MRI/CT and lung CT scans.
2018-02
PR Newswire
Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning
Arterys Inc. received its fifth 510(k) clearance from the FDA for the Arterys Oncology AI suite, expanding its clinical offerings with AI-powered workflows for medical imaging interpretation. The software helps clinicians measure and track tumors or potential cancers and apply radiological standards for liver MRI/CT and lung CT scans.
2018-02
Applied Radiology
Arterys receives FDA 510(k) for oncology imaging software
Arterys' Oncology AI imaging software received 510(k) clearance from the FDA, providing a web-based suite to assist radiologists and oncologists in measuring and tracking tumors. The initial deep learning workflows are for liver CT and MRI, and lung CT scans.
2018-03
Fierce Biotech
GE-backed deep learning startup Arterys bumps up Series A to $12M+ as it nears cardio launch, goes into oncology
Arterys secured over $12 million in Series A financing to expand into oncology, aiming to apply deep learning to various oncology data, including imaging scans, EHRs, genomic data, and blood tests.
2016-03
Forbes
First FDA Approval For Clinical Cloud-Based Deep Learning In Healthcare
Arterys received FDA 510(k) clearance for its medical imaging platform, initially for cardiac diagnosis, and is now developing its next application for cancer.
2017-01
Medical Device Network
Arterys gains FDA clearance for AI oncology imaging suite
Arterys' Oncology AI suite received 510(k) clearance from the FDA for its AI-powered software that helps clinicians measure and track tumors. The initial deep learning workflows are for liver MRI/CT and lung CT scans.
2018-02
Imaging Technology News
Arterys | Imaging Technology News
Arterys announced a $30M Series B financing round to expand its AI platform and launch products in oncology and neurology, as well as accelerate commercialization of its cardiac offering.
2015-12
FDA
K173542 - 510(k) Premarket Notification
This FDA 510(k) Premarket Notification document details the clearance for Arterys Oncology DL, a medical diagnostic application from Arterys, Inc.
2026-06

Videos

Product demos, reviews, and walkthroughs for Arterys Oncology DL.

View all on YouTube

Frequently Asked Questions

Arterys Oncology DL is an FDA-cleared, AI-powered medical imaging software designed to automate the segmentation and tracking of lung nodules and liver lesions in CT and MRI scans. It aids clinicians by providing tools for confirming, evaluating, quantifying, and reporting on the presence or absence of these lesions, thereby enhancing diagnostic efficiency and accuracy.
Arterys Oncology DL has received FDA 510(k) clearance and operates on the Arterys Medical Imaging Cloud (MICA) platform, which ensures compliance with patient data privacy and security requirements. This platform adheres to regulations across 27 countries, including the U.S. and Europe, and is HIPAA compliant.
The software is designed to integrate into existing PACS or EHR-driven workflows, making it a natural extension of current practices. While it automates segmentations, clinicians always retain the capability to edit these automated results, ensuring they remain in ultimate control of the diagnosis.
Currently, Arterys Oncology DL primarily focuses on the automated segmentation and tracking of lung nodules and liver lesions in CT and MRI scans. While there are plans to expand to other solid tumors and organs, its initial and primary workflows are concentrated on these specific areas.
Yes, there are several other AI-based medical imaging solutions available that offer clinical decision support for oncology. These include tools like Veye Chest for pulmonary nodules, QyScore for brain lesions, and other general AI platforms for image analysis from various companies.
Specific pricing for Arterys Oncology DL is not publicly disclosed. Interested parties are advised to contact the Arterys Sales team directly to request a personalized quote based on their specific requirements.

Related Tools

SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
CerviCARE AI
NTL Healthcare
OB/GYN AI
CerviCARE AI is an AI-powered cervical cancer screening system that analyzes smartphone images of the cervix to predict findings, aiming for early detection.
Lumonus AI
Lumonus
Clinical Decision Support & Reference
Lumonus AI is an AI-powered software that assists healthcare providers with prescriptions, dosing, and treatment for cancer patients, with a module (Sigma) that suggests treatment protocols based on prior plans for similar patients.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

See all Oncology AI tools →

More from ARTERYS

Arterys MICA
Arterys (now part of Tempus)
Radiology & Imaging AI
Arterys MICA is a cloud-based AI platform for medical imaging analysis, designed for radiologists and clinicians to enhance diagnostic processes with automated image analysis, real-time collaboration, and scalable cloud computing for various modalities like CT and MRI.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-20 | First Added: 2026-04-20
AI Tool Finder
AI-powered search. Results may not be comprehensive.